Drugs / VP-001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06455826 | Jun 2024 → Sep 2025 | retinitis pigmentosa 11 | PYC Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05902962 | Apr 2023 → Aug 2025 | retinitis pigmentosa 11 | PYC Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06852963 | Jun 2025 → Mar 2028 expected | retinitis pigmentosa 11 | PYC Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VP-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05902962 ↗ |
| Modality | Oligonucleotide (other) | “VP-001 is an oligonucleotide-peptide conjugate administered intravitreally.” NCT06852963 ↗ |
| Route | Intravitreal | “Intravitreally Administered VP-001” NCT05902962 ↗ |